Login
Companies $MBX
$53.12 -$2.82 (5.04%) Live
MBX Biosciences, Inc. logo

MBX Biosciences, Inc.

mbxbio.com

What Do They Do?

Develops peptide drug candidates for patients with endocrine and metabolic disorders, including chronic hypoparathyroidism, obesity and post-bariatric hypoglycemia.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −189% (Loss)
vs −$21.6M in Q3 FY2025
  • Aug 6, 2026 CEO and CFO appointments announced Steve Hoerter succeeded Kent Hawryluk as CEO; John Smither was appointed CFO.

Who Do They Compete With?

Competes with Ascendis Pharma, AstraZeneca, Extend Biosciences, Septerna, BridgeBio/Calcilytix, Eli Lilly and, Novo Nordisk, Amgen, Roche, Viking Therapeutics, Zealand Pharma, Boehringer Ingelheim, Amylyx Pharmaceuticals, Vogenx, and Recordati

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support